At-Risk Launches: Neurontin Settlement Leaves Question Of Jury Damage Calculations Unresolved
This article was originally published in The Pink Sheet Daily
Executive Summary
Teva and Actavis settle with Pfizer two weeks into a jury trial to determine liability and damages for launching generic gabapentin at-risk.
You may also be interested in...
At-Risk Launches: Three Cases May Determine How Damages Are Calculated
How risky are at-risk launches of generic products?
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
One Trial Plus Supportive Evidence Is Enough For Hospital-, Ventilator-Acquired Pneumonia Indication, Panel Says
Anti-Infective Drugs Advisory Committee members viewed one-trial as practical means of gaining efficacy data.